Meeting
2018 ASCO Annual Meeting
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study.
Authors
Francesco De Rosa
Immunotherapy, Cell Therapy and Biobank, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy
Francesco De Rosa , Laura Ridolfi , Enrica Teresa Tanda , Elena Marra , Jacopo Pigozzo , Riccardo Marconcini , Michele Guida , Giulia Gallizzi , Marcella Occelli , Laura Pala , Elisabetta Gambale , Melissa Bersanelli , Raffaele Conca , Alessio Cortellini , Francesca Morgese , Federica Zoratto , Luigia Stefania Stucci , Sabino Strippoli , Elisabetta Petracci , Massimo Guidoboni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Geriatric Oncology
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10038)
DOI
10.1200/JCO.2018.36.15_suppl.10038
Abstract #
10038
Poster Bd #
26
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.
First Author: Harsh V Parmar
Poster
2018 ASCO Annual Meeting
Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
First Author: Shelly Ann Christiansen
Poster
2022 ASCO Annual Meeting
A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
First Author: Geoffrey Thomas Gibney